GH Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

$157.12  -2.40 (-1.51%)
As of 04/09/2021 15:59:53 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  USA
Country of incorporation:  USA
IPO date:  10/04/2018
Outstanding shares:  100,426,884
Average volume:  820,181
Market cap:   $15,784,093,358
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    40131M109
ISIN:        US40131M1099
Sedol:      BFXC911
Valuation   (See tab for details)
PE ratio:   -62.20
PB ratio:   12.13
PS ratio:   55.05
Return on equity:   -19.54%
Net income %:   -88.51%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy